{"classes":[{"categories":[{"measurements":[{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"}]}],"title":"Grade 1 Non-serious Solicited - Hemorrhoidal hemorrhage"},{"categories":[{"measurements":[{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"3"}]}],"title":"Grade 1 Non-serious Solicited - Hypertension"},{"categories":[{"measurements":[{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"}]}],"title":"Grade 1 Non-serious Solicited - Nasal congestion"},{"categories":[{"measurements":[{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"}]}],"title":"Grade 1 Non-serious Solicited - Arthralgia"},{"categories":[{"measurements":[{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]}],"title":"Grade 1 Non-serious Solicited - Weight gain"},{"categories":[{"measurements":[{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"}]}],"title":"Grade 2 Non-serious Solicited - Conjunctivitis"},{"categories":[{"measurements":[{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"3"}]}],"title":"Grade 2 Non-serious Solicited - Infections and infestations - Other COVID, specify"},{"categories":[{"measurements":[{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"}]}],"title":"Grade 2 Non-serious Solicited - Neutrophil count decreased"},{"categories":[{"measurements":[{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"}]}],"title":"Grade 2 Non-serious Solicited - Pneumonitis"},{"categories":[{"measurements":[{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"title":"Grade 2 Non-serious Solicited - Dental caries"},{"categories":[{"measurements":[{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"title":"Grade 2 Non-serious Solicited - Hypothyroidism"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"description":"Solicited (expected) local and systemic Adverse Reactions (ARs) through 7 days after each injection were assessed using the clinical abnormalities section of the Food and Drug Administration (FDA) -Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. Unsolicited (unexpected) adverse events (AEs) through 28 days after each injection and serious adverse events (SAE's) throughout the entire study period were assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Grade 1 is mild. Grade 2 is moderate. Grade 3 is severe. Grade 4 is life-threatening. Grade 5 is death related to adverse event.","groups":[{"description":"100 mcg (0.5 mL) messenger ribonucleic acid (mRNA)-1273 injection on day (D)1.","id":"OG000","title":"Chronic Lymphocytic Leukemia (CLL) Not on Active Therapy - Booster Phase"},{"description":"100 mcg (0.5 mL) messenger ribonucleic acid (mRNA)-1273 injection on day (D)1.","id":"OG001","title":"Chronic Lymphocytic Leukemia(CLL) Receiving Bruton´s Tyrosine Kinase(BTK) Interruption-Booster Phase"},{"description":"100 mcg (0.5 mL) messenger ribonucleic acid (mRNA)-1273 injection on day (D)1.","id":"OG002","title":"Chimeric Antigen Receptor (CAR) T Cell Therapy - Booster Phase"},{"description":"100 mcg (0.5 mL) messenger ribonucleic acid (mRNA)-1273 injection on day (D)1.","id":"OG003","title":"Solid Tumor on Programmed Cell Death protein1/Programmed Cell Death Ligand 1 Inhibitor-Booster Phase"},{"description":"100 mcg (0.5 mL) messenger ribonucleic acid (mRNA)-1273 injection on day (D)1.","id":"OG004","title":"Post Allogeneic Transplant - Booster Phase"},{"description":"100 mcg (0.5 mL) messenger ribonucleic acid (mRNA)-1273 injection, intramuscular (IM) on day 1.","id":"OG005","title":"Other Hematologic Malignancy - Booster Phase"},{"description":"100 mcg (0.5 mL) messenger ribonucleic acid (mRNA)-1273 injection on day (D)1.","id":"OG006","title":"Other Adult Solid Tumor - Booster Phase"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"No participants were enrolled in Groups CLL, CLL/BTK, CAR-T Cell and Other Adult Solid Tumor Booster Phase. Regarding Other Hematologic Malignancy Booster Phase Group 1 participant crossed over from hematologic low immunosuppression-initial phase; 3 participants crossed over from hematologic intermediate immunosuppression-initial phase; 3 participants crossed over from hematologic high immunosuppression-initial phase; \\& 3 participants were initially enrolled (did not cross over) into this group.","reportingStatus":"POSTED","timeFrame":"7 and 28 days after each injection and throughout the entire study period, a median of 19.5 months","title":"Number of Participants With Grades 1-5 Solicited (Expected) and/or Unsolicited (Unexpected) Adverse Events (AE's): Booster Phase","type":"PRIMARY","unitOfMeasure":"Participants"}